[Anti-vascular endothelian growth factor therapy in the field of oncology]

Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• Angiogenesis suppression has been a long-standing strategy in oncology.
• The clinical efficacy of anti-angiogenic therapies is well-documented but often limited.
• Growing indications for anti-angiogenic drugs exist, yet their overall impact requires further evaluation.

Purpose of the Study:

• To review the current state and limitations of anti-angiogenesis therapy in oncology.
• To explore the potential of combining anti-angiogenic drugs with immunotherapy.
• To highlight the role of biomarkers in personalizing cancer treatment.

Main Methods:

• Literature review of studies on anti-angiogenesis and cancer therapy.
• Analysis of clinical trial data regarding combination therapies.
• Examination of the tumor microenvironment's immunomodulatory effects.

Main Results:

• While anti-angiogenesis is established, its clinical impact is frequently restricted.
• Emerging evidence supports the clinical significance of angiogenesis inhibition across various treatments.
• Lack of predictive biomarkers hinders personalized treatment strategies.

Conclusions:

• Combination therapy of anti-angiogenic drugs and immunotherapy shows significant promise.
• The anti-immune nature of the tumor microenvironment can be modulated by combination treatments.
• Future cancer therapy may be significantly altered by integrating anti-angiogenesis and immunotherapy.